Prostate cancer trials in United Kingdom

In United Kingdom 105 Also abroad 1481

105 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
London, Middlesbrough, Southampton, Truro
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Cambridge, Cardiff, Leeds, London, Newcastle upon Tyne, Southampton, Sutton
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
No phaseNot yet taking people in United Kingdom
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Where
Sutton
Age
18 years and over
People
9,007
Run by
Royal Marsden NHS Foundation Trust
See details and how to joinNCT07870707
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
London, Oxford, Sutton, Windsor
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Cambridge, Glasgow, London, Manchester, Plymouth
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford, London, Manchester, Newcastle, Plymouth, Preston, Romford
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Blackburn, Cardiff, London, Maidstone, Manchester, Plymouth, Torquay
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Cambridge, London
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
London, Sutton
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
No phaseNot yet taking people in United Kingdom
Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer
Where
London
Age
18 years and over
People
100,000
Run by
Imperial College London
See details and how to joinNCT07264088
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Glasgow, Scotland, London, Newcastle upon Tyne
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
London, Newcastle upon Tyne
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Cambridge, London, Middlesex
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
HTL0039732 in Participants With Advanced Solid Tumours
Where
Cambridge, Cardiff, Dundee, Liverpool, London, Manchester
Age
18 years and over
People
150
Run by
Cancer Research UK
See details and how to joinNCT05944237
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
London
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 1Taking people
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Where
Leicester, London, Sutton
Age
18 years and over
People
83 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Cambridge, Dundee, London, Manchester
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseNot yet taking people in United Kingdom
Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.
Where
Liverpool
Age
18 years and over
People
40
Run by
The Clatterbridge Cancer Centre NHS Foundation Trust
See details and how to joinNCT07837063
No phaseTaking people
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Where
Coventry
Age
18 years and over
People
850 worldwide
Run by
XEOS Medical
See details and how to joinNCT06970275
No phaseTaking people
PRostate Cancer Enhanced Diagnosis by Calibration Technology
Where
London
Age
18 years and over
People
66
Run by
Gold Standard Phantoms
See details and how to joinNCT06607783
No phaseNot yet taking people in United Kingdom
Advanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)
Where
London
Age
18 years and over
People
660
Run by
University College, London
See details and how to joinNCT07808528
Phase 1/2Taking people
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Where
Belfast, Cambridge, Sutton
Age
18 years and over
People
78 worldwide
Run by
Institute of Cancer Research, United Kingdom
See details and how to joinNCT07002320
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
London
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1/2Taking people
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Where
Cambridge, Manchester
Age
18 years and over
People
52 worldwide
Run by
AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00